Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.

Milecki P, Baczyk M, Skowronek J, Antczak A, Kwias Z, Martenka P.

J Biomed Biotechnol. 2009;2009:625394. doi: 10.1155/2009/625394. Epub 2009 Oct 22.

PMID:
19859572
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52.

PMID:
11483335
[PubMed - indexed for MEDLINE]
3.

Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.

Mantini G, Tagliaferri L, Mattiucci GC, Balducci M, Frascino V, Dinapoli N, Di Gesù C, Ippolito E, Morganti AG, Cellini N.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e721-6. doi: 10.1016/j.ijrobp.2010.12.003. Epub 2011 Jan 27.

PMID:
21277100
[PubMed - indexed for MEDLINE]
4.

Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer.

Takaha N, Okihara K, Kamoi K, Kimura Y, Yamada T, Kawauchi A, Kobayashi K, Yamazaki H, Nishimura T, Miki T.

Urol Int. 2011;87(1):28-34. doi: 10.1159/000324478. Epub 2011 Jun 23.

PMID:
21701133
[PubMed - indexed for MEDLINE]
5.

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group.

Lancet Oncol. 2005 Nov;6(11):841-50.

PMID:
16257791
[PubMed - indexed for MEDLINE]
6.

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P.

Eur Urol. 2012 Aug;62(2):213-9. doi: 10.1016/j.eururo.2012.03.053. Epub 2012 Apr 3.

PMID:
22502942
[PubMed - indexed for MEDLINE]
7.

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU.

N Engl J Med. 2011 Jul 14;365(2):107-18. doi: 10.1056/NEJMoa1012348.

PMID:
21751904
[PubMed - indexed for MEDLINE]
Free Article
8.

Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.

Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S.

J Clin Oncol. 2005 Sep 20;23(27):6561-8.

PMID:
16170164
[PubMed - indexed for MEDLINE]
Free Article
9.

High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?

Cellini N, Pompei L, Fortuna G, Ammaturo MV, De Paula U, Luzi S, Mattiucci GC, Morganti AG, Digesù C, Rosetto ME, Palloni T, Petrongari MG, Gentile P, Deodato F, Valentini V.

Tumori. 2004 Mar-Apr;90(2):201-7.

PMID:
15237583
[PubMed - indexed for MEDLINE]
10.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
[PubMed - indexed for MEDLINE]
11.

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.

Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE.

Urology. 1997 Mar;49(3A Suppl):46-55.

PMID:
9123736
[PubMed - indexed for MEDLINE]
12.

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.

DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.

BJU Int. 2009 Nov;104(9):1208-14. doi: 10.1111/j.1464-410X.2009.08593.x. Epub 2009 Apr 17.

PMID:
19388987
[PubMed - indexed for MEDLINE]
13.

Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Hirano D, Nagane Y, Satoh K, Mochida J, Sugimoto S, Ichinose T, Takahashi S, Maebayashi T, Saitoh T.

Int Urol Nephrol. 2010 Mar;42(1):81-8. doi: 10.1007/s11255-009-9580-7. Epub 2009 May 16.

PMID:
19449118
[PubMed - indexed for MEDLINE]
14.

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):23-30. doi: 10.1016/j.ijrobp.2009.01.030. Epub .

PMID:
19395187
[PubMed - indexed for MEDLINE]
15.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55. Epub 2007 May 24.

PMID:
17531401
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

PMID:
22893254
[PubMed - indexed for MEDLINE]
Free Article
17.

Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 24.

PMID:
22836052
[PubMed - indexed for MEDLINE]
18.

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.

Payne H, Mason M.

Br J Cancer. 2011 Nov 22;105(11):1628-34. doi: 10.1038/bjc.2011.385. Epub 2011 Oct 18. Review.

PMID:
22009028
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?

Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath R, Adamovich E.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1078-84. doi: 10.1016/j.ijrobp.2009.02.069. Epub 2009 Jun 24.

PMID:
19553031
[PubMed - indexed for MEDLINE]
20.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk